Tomorrow Accelerated.

We build the DNA that powers genetic medicine and translate it into clinical grade therapies through integrated manufacturing.

Artis transforms promising science into clinical reality

As the first company to combine proprietary synthetic DNA manufacturing with advanced therapy development and GMP manufacturing, Artis provides a connected path from starting material to clinical production. Our integrated platform helps genetic medicine developers move faster, reduce complexity, and maintain greater control throughout development.

With operations in the United States and Europe, Artis supports programs spanning cell therapy, gene therapy, mRNA, gene editing, vaccines, and other advanced therapeutic modalities. By bringing synthetic DNA, process development, and GMP manufacturing together under one organization, we help transform promising science into clinical reality.

Modalities

Supporting Multiple Advanced Therapy Modalities on One Platform

Because we control the starting material, we can optimize the entire downstream path. Our platform supports the broadest range of advanced therapy modalities from a single, integrated infrastructure:

Services

An Integrated Platform from Starting Material to the Clinic

Artis provides fully integrated services with disciplined, end-to-end execution to accelerate advanced therapy medicinal products (ATMPs) from synthetic DNA through GMP manufacturing, all within a single quality framework. Our model eliminates the handoffs, vendor transitions, and knowledge loss that slow programs down.

SYNthetic DNA

Our oDNA Platform

Truly synthetic oDNA — your gene of interest, enzymatically produced to gram scale, free of biological contamination — is the superior starting material for every application in genetic medicine.

Our Leadership

Artis BioSolutions is led by a team that has collectively deployed over $250 million in capital across seven GMP facilities, launched 50+ active pharmaceutical ingredients, and scaled technologies from bench to global commercial use. Our leadership spans synthetic DNA technology, advanced therapy manufacturing, process science, business development, and commercial strategy.

Brian Neel

Founder & Chief Executive Office

Brian brings 25 years of experience in the life science and diagnostic industries to Artis. Brian specializes in leading and optimizing business operations with a history of first-to-market successes. Through his unique ability to develop highly flexible teams, facilities and capabilities, Brian shifts businesses towards new markets and next-generation platforms - underscoring Artis' capability to expand and innovate without compromising efficiency.

Mike Houston, Ph.D.

Founder & Chief Scientific Officer

Mike holds a Ph.D. in bioorganic chemistry and has led scientific operations and strategies across biotechnology and pharmaceutical companies. Mike specializes in oligonucleotide, protein/ peptide/lipid nanoparticle-based drug products & delivery formulations and analytical development - setting new standards for quality and compliance in genomic medicine.

Kate Broderick

Chief Scientific & Innovation Office

Kate Broderick is a life sciences executive with two decades of leadership across biotech, CDMOs, and biopharma. She brings deep expertise in gene delivery, vaccines, and immunotherapies, paired with a passion for clear communication.

Eric Stier

Chief Legal Officer

Eric brings nearly 25 years of legal leadership across high-growth and complex life sciences organizations. His expertise spans corporate law, intellectual property, governance, M&A, and litigation, with a track record advising on major transactions in the biotech and diagnostics space. Eric pairs deep legal acumen with a commitment to companies advancing healthcare and clinical research.

Peter Stolba

Chief Business Officer

Peter has held global leadership roles in Business Development, M&A, licensing, and operations across biotech, pharma, and related sectors. His experience spans end-to-end development across diverse modalities and therapeutic areas. At Artis, Peter leverages his strategic expertise to lead growth initiatives and scale businesses.

Gregg Nyberg

Chief Technology Officer

Gregg Nyberg, Ph.D., brings more than 20 years’ biopharmaceutical industry experience. Most recently, he was associate vice president at Merck, where he led the company’s biologics process development and clinical manufacturing organizations. He also spent nearly 15 years in positions of increasing responsibility at Amgen including key leadership roles in process development and cell sciences and technology.

Landmark Bio

Amanda Owens

Senior Vice President, Commercial

Amanda Owens brings over 10 years of leadership in biotech commercial strategy and operations, guiding companies through growth inflection points in go-to-market planning, external partnerships, and investor engagement. Amanda leads commercial strategy and external engagement, helping translate advanced cell and gene therapy manufacturing into accessible patient therapies.

Eli Kraus

Vice President, Process Development & Analytics

Eli Kraus Ph.D. has been in the biotechnology field for more than 25 years with experience in process development, clinical and commercial GMP manufacturing, technology transfer and CMC. Prior to Landmark Bio Dr. Kraus had an extensive career at Amgen in Process Development, supporting programs from clinical development through commercialization. Dr. Kraus is focused on bringing GMP innovation, for our clients as they progress from bench to clinic.

Michael Sousa

Vice President, Quality Site Head

Michael Sousa brings over 25 years of comprehensive quality leadership to LandmarkBio, specializing in quality assurance, control, systems, and robust supplier / partner oversight. His extensive career spans recombinant proteins and cutting-edge cell and gene therapies, supporting programs from early clinical development to commercialization. Michael excels at establishing, scaling, and optimizing quality systems within fast-paced, highly complex, and tightly regulated environments.

Kris Ward

Vice President, Corporate Development & Licensing

Kris Ward joined the company in April 2022 and has played an instrumental role in the success of Landmark Bio. Under his leadership, the Business Development team built a strong pipeline and delivered 4-fold revenue increase year-over-year in an extremely challenging market. Prior to Landmark Bio, Kris was at Orchard Therapeutics for four years where he held various roles culminating with him leading Alliance Management and Business Operations.

Syngoi Technologies

José Vicente Pons Andreu

CEO

José Vicente Pons Andreu is a serial entrepreneur, biotech executive, and business angel with extensive experience founding, scaling, and successfully exiting innovative life sciences companies. He has held CEO and board-level positions across biotechnology, healthcare, diagnostics, and consumer health sectors. Currently, he serves as CEO of Syngoi Technologies and Operating Partner at Columbus Venture Partners, supporting the growth and international expansion.

Julen Oyarzabal

Chief Scientific Officer

Julen Oyarzabal, PhD has over 25 years of experience in drug discovery, biotechnology, and the biopharmaceutical industry. For the past eight years, he serves as Partner and Chief Scientific Officer at Columbus Venture Partners, leading scientific strategy, company creation, technology evaluation, and investment activities. Previously, he held leadership roles at Johnson & Johnson, CNIO, and CIMA–University of Navarra, served for seven years on the European Medicines Agency (EMA) expert panel, and co-founded Syngoi, a Columbus-backed synthetic DNA manufacturing company. He is co-inventor of over 35 patent families and author of more than 100 peer-reviewed scientific publications.

Seamless Integration at Any Stage

Artis meets your program where it is — from early development through clinical GMP — working within your timeline, budget, and resources to reach the next milestone.

By uniting synthetic DNA, process and analytical development, GMP manufacturing, and CMC regulatory expertise on a single platform, we eliminate the handoffs and vendor fragmentation that slow programs down, preserving technical continuity from starting material to clinical supply.

We advance your program by meeting you where you are.

Get in Touch

"*" indicates required fields